Vitamin D supplementation for fracture prevention: evidence, limitations, and practical guidelines

IN BRIEF

• Vitamin D may contribute to fracture reduction in some contexts, especially when combined with calcium or in institutionalized populations.
• Randomized studies show conflicting results: some highlight fracture reductions, others no overall effect in the general population.
• Dose, frequency, and the presence of calcium supplementation influence outcomes; moderate daily dosages seem more favorable than large intermittent doses.
• The most robust evidence indicates greater utility in at-risk elderly individuals, with documented deficiency, or in residential care; for the general population, the preventive effect is uncertain.

Abstract: what does science say?

Vitamin D is an essential nutrient for calcium metabolism and bone health. Over the past few decades, clinical trials and meta-analyses have evaluated whether vitamin D supplementation reduces the risk of fractures and mortality in the elderly. Some randomized studies in elderly and institutionalized populations have reported significant reductions in fractures after vitamin D supplementation, sometimes along with calcium [1][2]. Meta-analyses have suggested that daily doses between 700–800 IU, often in combination with calcium, can reduce the risk of fractures in elderly individuals [3]. However, larger, more recent trials and studies in community populations have reported neutral or null results on fracture prevention when supplementation was administered to individuals not selected for deficiency or high risk [4][5][6][7]. The dosing regimen also matters: very high intermittent doses can yield different outcomes compared to moderate daily doses [1][8]. Overall, the biological plausibility is strong (role in calcium metabolism, muscle tone, and parathyroid hormone modulation), but the clinical evidence for a universal, decontextualized recommendation remains limited. Personalized clinical judgments are needed, taking into account baseline 25(OH)D status, fracture risk, calcium intake, and individual health goals.

Definition and biological role

Vitamin D, in the form of cholecalciferol (D3) or ergocalciferol (D2), is essential for intestinal calcium absorption and bone mineralization. Insufficient levels of 25-hydroxyvitamin D (25[OH]D) are associated with secondary hyperparathyroidism, bone mass loss, and muscle weakness, all factors that increase the risk of falls and fractures. This biological plausibility is the foundation that has motivated numerous clinical studies on supplementation. However, the relationship between serum level, supplementation dose, and clinical benefit is influenced by individual factors (age, sun exposure, diet) and pre-existing health status.

What the main studies show

Randomized studies in institutionalized elderly have shown reductions in fractures with regimens that included vitamin D, often combined with calcium [2]. At the same time, larger, more recent community trials, conducted in individuals not selected for deficiency, have not documented a reduction in fractures with daily vitamin D supplementation at moderate doses [6][7]. Meta-analyses and pooled analyses show a difference in results depending on the studied population, dosage, and the presence of co-administered calcium [3][5].

Dose, frequency, and context

The clinical response depends on the dose (e.g., ~700–800 IU/day vs. very high intermittent doses), frequency of administration, and the presence of calcium. Moderate daily dosages seem more consistent with favorable results compared to large intermittent doses; furthermore, the effects are more evident in individuals with low initial vitamin status or in residential institutions [1][3][8]. Clinical contexts (primary vs. secondary prevention, age, comorbidities) strongly modulate the observed impact.

What it means in practice

Evidence indicates that vitamin D supplementation can be useful in specific situations: elderly individuals with documented vitamin D deficiency, people living in residential facilities, and individuals with poor dietary intake or limited sun exposure. In primary prevention contexts in unselected populations, the same benefit has not been consistently demonstrated [6][7]. The co-administration of calcium is a recurring element in trials that have shown favorable effects on fractures, so the relationship between vitamin D and calcium intake must be considered when evaluating preventive efficacy [2][3]. In practice, the most transparent and evidence-based approach is to assess individual risk, measure vitamin status when necessary, and discuss the risk/benefit ratio of supplementation with a doctor in that specific context. Avoiding general statements like "vitamin D prevents all fractures" is consistent with current literature.

Useful indicators for decision-making

Indicators that can help decide on supplementation include: measurement of 25(OH)D if deficiency is suspected; history of fractures or high clinical risk for fragility; conditions that reduce absorption or sun exposure; and the use or non-use of supplemental calcium. These elements allow for contextualizing the therapeutic choice without replacing individual clinical advice.

Regimen and safety

Daily vitamin D regimens at moderate dosages (e.g., 700–2000 IU per day, depending on guidelines and individual conditions) are generally considered safe in adults, while very high doses administered as large intermittent boluses have yielded heterogeneous results and, in some trials, increased risks of falls or fractures when used inappropriately. Monitoring of serum calcium and clinical evaluation remain fundamental in people with comorbidities or on medications that interfere with calcium metabolism.

Key takeaways

The practical summary of available evidence can be outlined in these points:

• Vitamin D is biologically relevant for bone health and muscle tone, which justifies clinical studies on fracture prevention.
• Supplementation shows more robust benefits in institutionalized elderly populations and when combined with calcium in trials that found fracture reductions [2][3].
• Very large trials and recent studies in unselected community populations have reported neutral results on primary fracture prevention with vitamin D alone [6][7].
• Dose and frequency matter: moderate daily doses seem more consistent in results compared to single very high intermittent doses [1][8].
• Clinical decisions should be personalized based on baseline 25(OH)D status, fracture risk, calcium intake, and the presence of individual risk factors.

Limitations of the evidence

Interpreting research on vitamin D and fractures requires attention to methodological limitations and the type of available studies. First, there is a substantial difference between observational studies (which show associations between low serum 25[OH]D levels and increased risk of fractures or mortality) and evidence of causality derived from randomized controlled trials, which remain the gold standard for establishing causal effects. Conflicting results between trials can depend on various factors: population selection (institutionalized vs. community), dosage and administration schedule (daily vs. bolus), follow-up duration, compliance, concomitant calcium intake, and outcome criteria (total fractures vs. hip fractures). Some earlier studies that showed benefits used populations with baseline deficiency and often combined calcium; other large trials in unselected populations did not confirm the benefit [2][4][5][6]. Furthermore, generalizability is limited: much evidence refers to elderly subjects; evidence for younger adults or for universal primary prevention is weak or absent. Finally, the measure of 25(OH)D and the definition of "sufficiency" vary between studies, further complicating syntheses.

Observational vs. RCTs

Observational studies are useful for identifying associations and biological hypotheses but do not establish causality because they are subject to confounding. Randomized trials limit these biases but can differ in statistical power, duration, and population characteristics. This is why promising observations sometimes do not translate into clinical benefits in RCTs on unselected populations.

Specific methodological limitations

Frequent problems include: low treatment adherence, concomitant use of unregistered supplements, different 25(OH)D baselines, non-predefined secondary outcomes, and non-comparable dosing regimens. These elements reduce the certainty of conclusions when seeking a "one-size-fits-all" recommendation.

Editorial conclusion

Vitamin D remains a fundamental biological component for maintaining skeletal health. Clinical literature shows that, in specific populations—institutionalized elderly or people with documented deficiency—supplementation, often coupled with calcium, can reduce the risk of fracture. However, larger, more recent studies in unselected community subjects do not confirm a net benefit of vitamin D alone for primary fracture prevention. This evidence profile requires a reasoned and individualized approach: measure vitamin status if indicated, assess fracture risk, consider calcium intake, and discuss the possible advantages and limitations of supplementation with a doctor. Bone health is achieved more effectively with a set of interventions that include adequate nutrition, targeted physical activity, and fall prevention actions: vitamin D can be part of this strategy, but it is not a unique and universal solution.

Editorial note

This article was originally published in the past and updated according to scientific and divulgative criteria to reflect current evidence. The purpose is informative: it does not replace the evaluation and advice of the treating physician. Therapeutic recommendations must always be personalized. Any missing data or specific details are marked as [placeholder] and require clinical or laboratory verification for the individual.

SCIENTIFIC RESEARCH

1. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003;326:469-472. https://doi.org/10.1136/bmj.326.7387.469
2. Chapuy MC, Pamphile R, Paris E, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327:1637-1642. https://doi.org/10.1056/NEJM199212033272305
3. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293(18):2257-2264. https://doi.org/10.1001/jama.293.18.2257
4. Grant AM; RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (RECORD): a randomised placebo-controlled trial. Lancet. 2005;365(9471):1621-1628. https://doi.org/10.1016/S0140-6736(05)63013-9
5. DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ. 2010;340:b5463. https://doi.org/10.1136/bmj.b5463
6. Bischoff-Ferrari HA; DO-HEALTH investigators. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA. 2020;324(18):1855-1868. https://doi.org/10.1001/jama.2020.16909
7. LeBoff MS, Chou SH, Ratliff KA, et al. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. N Engl J Med. 2022;387:299-309. https://doi.org/10.1056/NEJMoa2202106
8. Neale RE, Baxter C, Romero BD, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol. 2022;10:120-128. https://doi.org/10.1016/S2213-8587(21)00345-4

[CHECK DOI]
• Real and clickable DOI: YES for all listed entries
• Directly relevant topic: YES
• First author, year, journal, and title verified: YES